Top-Rated StocksTop-RatedNASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free IMCR Stock Alerts $37.87 -0.59 (-1.53%) (As of 11:48 AM ET) Add Compare Share Share Today's Range$37.67▼$38.5150-Day Range$38.46▼$61.9152-Week Range$37.67▼$76.98Volume62,727 shsAverage Volume630,816 shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/APrice Target$81.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunocore alerts: Email Address Immunocore MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside112.8% Upside$81.85 Price TargetShort InterestBearish13.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.88) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.21 out of 5 starsMedical Sector551st out of 913 stocksBiological Products, Except Diagnostic Industry82nd out of 152 stocks 4.4 Analyst's Opinion Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunocore has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.78% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Immunocore has recently increased by 29.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMCR. Previous Next 3.3 News and Social Media Coverage News SentimentImmunocore has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Immunocore this week, compared to 3 articles on an average week.Search Interest1 people have searched for IMCR on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Immunocore is held by insiders.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.88) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -31.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -31.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsAre you prepared for a financial lockdown?A new kind of American dystopia is being built before our eyes, and most people have no idea what's happening. That's why I've recorded this urgent message to give you all the details on how to prepare … Including three steps to take right now.Click here to watch my video before it's too late. About Immunocore Stock (NASDAQ:IMCR)Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More IMCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMCR Stock News HeadlinesJune 17 at 11:24 AM | americanbankingnews.comImmunocore (NASDAQ:IMCR) Reaches New 1-Year Low at $37.83June 1, 2024 | globenewswire.comImmunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseMay 31, 2024 | globenewswire.comImmunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024May 30, 2024 | globenewswire.comImmunocore to present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comImmunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaMay 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS) and Immunocore Holdings (IMCR)May 24, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)May 24, 2024 | barrons.comCancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.May 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Immunocore Holdings Amid Promising Brenetafusp Study and Strategic DevelopmentsMay 18, 2024 | investing.comImmunocore Holdings PLC (IMCR)May 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)May 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter ReportMay 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunocore Holdings on Strong KIMMTRAK Sales and Promising Pipeline GrowthMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)May 9, 2024 | markets.businessinsider.comImmunocore Holdings Outperforms with Kimmtrak Sales Surpassing Estimates; Maintains Buy RatingMay 9, 2024 | markets.businessinsider.comBuy Rating for Immunocore Holdings on Strong Financials and Expanding Innovative PipelineMay 8, 2024 | finance.yahoo.comImmunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue ForecastsMay 8, 2024 | investorplace.comIMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | finanznachrichten.deImmunocore Holdings plc: Immunocore reports first quarter financial results and provides a business updateMay 8, 2024 | globenewswire.comImmunocore reports first quarter financial results and provides a business updateApril 30, 2024 | msn.comLeerink Partners Initiates Coverage of Immunocore Holdings plc - Depositary Receipt () (IMCR) with Outperform RecommendationApril 26, 2024 | finanznachrichten.deImmunocore Holdings plc: Immunocore announces upcoming presentation and posters at ASCO 2024April 24, 2024 | globenewswire.comImmunocore announces upcoming presentation and posters at ASCO 2024April 11, 2024 | markets.businessinsider.comImmunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)See More Headlines Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees497Year FoundedN/APrice Target and Rating Average Stock Price Target$81.85 High Stock Price Target$100.00 Low Stock Price Target$67.00 Potential Upside/Downside+112.8%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-22.60% Pretax Margin-24.91% Return on Equity-16.54% Return on Assets-8.75% Debt Debt-to-Equity Ratio1.22 Current Ratio5.96 Quick Ratio5.94 Sales & Book Value Annual Sales$249.43 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book5.18Miscellaneous Outstanding Shares50,010,000Free Float45,461,000Market Cap$1.92 billion OptionableOptionable Beta0.83 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Bahija Jallal Ph.D. (Age 63)CEO & Executive Director Comp: $1.38MMr. Brian R. Di Donato M.B.A. (Age 57)CFO & Head of Strategy Comp: $654.46kMs. Tina St. Leger (Age 56)Chief Human Resources Officer Comp: $509.12kDr. David Berman M.D. (Age 53)Ph.D., Head of Research & Development Comp: $796.62kMr. John Trainer M.B.A. (Age 50)SVP & Chief Operating Officer Mr. John Goll IIISVP, Finance & Chief Accounting OfficerMs. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchMr. Sean D. Buckley (Age 41)VP & Chief Information Officer Clayton RobertsonHead of Investor RelationsMs. Lily Margaret HepworthGeneral Counsel & Company SecretaryMore ExecutivesKey CompetitorsVaxcyteNASDAQ:PCVXRepligenNASDAQ:RGENExelixisNASDAQ:EXELRevolution MedicinesNASDAQ:RVMDHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 6,510 shares on 5/17/2024Ownership: 0.013%Janus Henderson Group PLCBought 80,748 shares on 5/16/2024Ownership: 0.516%Jane Street Group LLCBought 28,700 shares on 5/16/2024Ownership: 0.000%Price T Rowe Associates Inc. MDSold 506,990 shares on 5/15/2024Ownership: 4.893%Bellevue Group AGSold 3,800 shares on 5/15/2024Ownership: 1.952%View All Insider TransactionsView All Institutional Transactions IMCR Stock Analysis - Frequently Asked Questions Should I buy or sell Immunocore stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMCR shares. View IMCR analyst ratings or view top-rated stocks. What is Immunocore's stock price target for 2024? 15 equities research analysts have issued 1-year price targets for Immunocore's shares. Their IMCR share price targets range from $67.00 to $100.00. On average, they predict the company's share price to reach $81.85 in the next year. This suggests a possible upside of 112.8% from the stock's current price. View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts. How have IMCR shares performed in 2024? Immunocore's stock was trading at $68.32 on January 1st, 2024. Since then, IMCR shares have decreased by 43.7% and is now trading at $38.46. View the best growth stocks for 2024 here. Are investors shorting Immunocore? Immunocore saw a increase in short interest in May. As of May 31st, there was short interest totaling 6,680,000 shares, an increase of 29.2% from the May 15th total of 5,170,000 shares. Based on an average daily volume of 699,900 shares, the days-to-cover ratio is presently 9.5 days. Approximately 13.8% of the shares of the stock are short sold. View Immunocore's Short Interest. When is Immunocore's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our IMCR earnings forecast. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.12. The company had revenue of $70.30 million for the quarter, compared to the consensus estimate of $70.72 million. Immunocore had a negative net margin of 22.60% and a negative trailing twelve-month return on equity of 16.54%. Immunocore's quarterly revenue was up 27.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.35) earnings per share. What ETFs hold Immunocore's stock? ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP) and Tema Oncology ETF (CANC).BlackRock Future Health ETF (BMED). When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an IPO on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.89%), Baker BROS. Advisors LP (3.04%), Bellevue Group AG (1.95%), Principal Financial Group Inc. (1.04%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.69%) and Janus Henderson Group PLC (0.52%). View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMCR) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.